中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (8): 703-716.doi: 10.35541/cjd.20250707

• 指南与共识 • 上一篇    下一篇

中国皮肤鳞状细胞癌诊疗指南(2026版)

中华医学会皮肤性病学分会    中国医师协会皮肤科医师分会   

  1. 中华医学会皮肤性病学分会    中国医师协会皮肤科医师分会
  • 收稿日期:2025-12-17 修回日期:2026-04-02 发布日期:2026-08-03
  • 通讯作者: 耿松梅;陈翔 E-mail:gengsongmei73@163.com; chenxiangck@126.com
  • 基金资助:
    国家自然科学基金委创新研究群体项目(82221002);陕西省重点产业创新链(群)-社会发展领域(2024SF?ZDCYL?01?14);陕西省卫生健康疑难罕见重症皮肤病诊疗科研创新平台(2025PT?05)

Chinese guideline for the diagnosis and treatment of cutaneous squamous cell carcinoma (2026 edition)

Chinese Society of Dermatology; China Dermatologist Association   

  1. Chinese Society of Dermatology; China Dermatologist Association
  • Received:2025-12-17 Revised:2026-04-02 Published:2026-08-03
  • Contact: Geng Songmei; Chen Xiang E-mail:gengsongmei73@163.com; chenxiangck@126.com
  • Supported by:
    The Innovative Research Group Project of the National Natural Science Foundation of China (82221002); Key Industrial Innovation Chain of Shaanxi Province (2024SF?ZDCYL?01?14); Shaanxi Provincial Health Commission Research Innovation Platform for Diagnosis and Treatment of Difficult, Rare and Severe Dermatological Diseases (2025PT?05)

摘要: 【摘要】 皮肤鳞状细胞癌(cSCC)是第二常见的皮肤恶性肿瘤,其早期诊断、规范治疗和科学预防具有重要临床意义。组织病理学检查目前仍是诊断cSCC的“金标准”。cSCC治疗策略因其分期而异。近年来免疫检查点抑制剂等系统治疗在高危型cSCC中取得了重要进展,但临床应用共识尚未形成。为整合最新循证证据,优化cSCC诊疗实践,本指南在《皮肤鳞状细胞癌诊疗专家共识(2021)》基础上,结合国内外最新临床研究进展及相关共识/指南,采用德尔菲法形成专家推荐意见。本次更新的主要内容:规范组织病理学检查流程,明确前哨淋巴结活检与淋巴结清扫术的适应证,以及免疫治疗、靶向治疗及新辅助治疗在cSCC中应用的最新临床数据与应用建议。本指南旨在为cSCC的规范化诊断与治疗提供基于循证医学的临床指导,提升我国cSCC的整体诊疗水平,改善患者预后。

关键词: 癌, 鳞状细胞, 治疗学, 诊断, 诊疗准则, 皮肤, 推荐意见

Abstract: 【Abstract】 Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy. Early diagnosis, standardized treatment, and scientific prevention are of critical clinical significance. Histopathological examination remains the gold standard for its definitive diagnosis. Treatment strategies for cSCC vary according to disease stages. In recent years, systemic therapies such as immune checkpoint inhibitors have shown important progress in the management of high?risk cSCC, though clinical consensus has not yet been established. To integrate the latest evidence and improve clinical practice for cSCC, this guideline updates the “Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma (2021)”. By incorporating recent advances in clinical research and relevant consensus recommendations from both Chinese and international sources, expert recommendations were formulated through the Delphi method. Key updates include standardizing the histopathological examination procedure, clarifying the indications for sentinel lymph node biopsy and lymph node dissection, and integrating the latest clinical data and application recommendations for immunotherapy, targeted therapy, and neoadjuvant therapy in cSCC. This guideline aims to provide evidence-based clinical guidance for the standardized diagnosis and treatment of cSCC in China, with the goal of improving the overall quality of care and patient outcomes.

Key words: Carcinoma, squamous cell, Therapeutics, Diagnosis, Practice guidelines, Skin, Recommendation

引用本文

中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 中国皮肤鳞状细胞癌诊疗指南(2026版)[J]. 中华皮肤科杂志, 2026,59(8):703-716. doi:10.35541/cjd.20250707

Chinese Society of Dermatology, China Dermatologist Association. Chinese guideline for the diagnosis and treatment of cutaneous squamous cell carcinoma (2026 edition)[J]. Chinese Journal of Dermatology, 2026, 59(8): 703-716.doi:10.35541/cjd.20250707